The diabetes market is ripe for innovation hence there is intense competition in the market. Some of the competitors are TNDM and DXCM, which both of great institutional sponsorship. The reason why PODD is up is due to the technical formation with a lower risk at a defined buy point. There is a consolidation base at the weekly chart and the daily chart is shaping up nicely although still with some 7% drops as shown. If it passes $234.09 with volume then it would be a great candidate to hold and observe the price action.
One of the great things about this company is that it is showing great earnings and has partnered up with DXCM to improve their product. Fundamentals are below
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
All ideas are for information purposes only. I may or may not invest in the stocks discussed.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.